🇺🇸 FDA
Patent

US 7910587

Quinoxalinyl dipeptide hepatitis C virus inhibitors

granted A61KA61K38/21A61P

Quick answer

US patent 7910587 (Quinoxalinyl dipeptide hepatitis C virus inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Mar 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Mar 22 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 17 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/21, A61P, A61P31/12